Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease

What happened

Amgen reported positive Phase 3 trial results for dazodalibep, a treatment being studied for Sjögren's disease. At week 48, treatment regimens met the main trial goal; the 1,500 mg group had a 5.6-point disease activity reduction versus 3.8 points with placebo, with adjusted p<0.001.

Confirmed

Global impact / market context

The results could support further development of dazodalibep and, if later approved, give Amgen a potential treatment for Sjögren's disease. Better disease activity scores and increased stimulated salivary flow may strengthen the case, while safety findings affect confidence in continued testing.

Analyst inference

The article reports trial results, not a regulatory approval or sales forecast. For Amgen, the near-term business effect therefore depends on what follows in development and review; commercial revenue, treatment uptake, and the cost of bringing the drug forward remain uncertain.

Analyst inference

What to watch

1. Watch for further trial details, including how the disease activity and salivary-flow improvements compare across the reported dazodalibep regimens and placebo. Analyst inference
2. Watch for any announcement from Amgen about next development steps or regulatory submissions; the article does not state that an application has been filed. Analyst inference
3. Track whether later updates confirm the reported balance in serious adverse events, treatment discontinuations, infections, and thromboembolic events across groups. Analyst inference

Evidence

• Original source link unavailable